You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Metastatic Castration Resistant

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Castration-resistant Prostate Cancer, mCRPC Trial in Seoul ([177Lu]Ludotadipep)

Recruiting
  • Metastatic Castration-resistant Prostate Cancer, mCRPC
  • Seoul, Korea, Republic of
    The Catholic University of Korea, Seoul, St, Mary's Hospital, 22
Dec 8, 2022

Castrate Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Prostate Cancer Trial in San Francisco

Not yet recruiting
  • Castrate Resistant Prostate Cancer
  • +3 more
  • San Francisco, California
    University of California, San Francisco
Mar 1, 2023

Castration-resistant Prostate Cancer, Metastatic Cancer Trial (Cabozantinib, Nivolumab)

Not yet recruiting
  • Castration-resistant Prostate Cancer
  • Metastatic Cancer
  • (no location specified)
Aug 12, 2022

Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Tumors, Prostate Cancer Recurrent Trial (lorigerlimab,

Not yet recruiting
  • Androgen-Independent Prostatic Cancer
  • +8 more
  • lorigerlimab
  • +2 more
  • (no location specified)
May 4, 2023

Prostate Cancer, Prostate Cancer Metastatic Trial in La Jolla (Abivertinib, Abiraterone)

Recruiting
  • Prostate Cancer
  • Prostate Cancer Metastatic
  • La Jolla, California
  • +1 more
Feb 2, 2023

Metastatic Castration-resistant Prostate Cancer, mCRPC Trial in Melbourne (Cabazitaxel, 177Lu-PSMA-617)

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • mCRPC
  • Melbourne, Victoria, Australia
    Peter MacCallum Cancer Centre
Jul 20, 2022

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Trial (AAA617, 68Ga-PSMA-11)

Not yet recruiting
  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • (no location specified)
Aug 16, 2023

Metastatic Castration-resistant Prostate Cancer (mCRPC) Trial (177Lu-PSMA-617, PSMA-11)

No longer available
  • Metastatic Castration-resistant Prostate Cancer (mCRPC)
  • (no location specified)
Jan 12, 2023

Metastatic Castration-resistant Prostate Cancer Trial in Tianjin (TABP EIC, Cyclophosphamide, fludarabine)

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • TABP EIC
  • +2 more
  • Tianjin, China
    Tianjin pepole's hosptial
Jul 28, 2022

Metastatic Castration Resistant Prostate Cancer Trial in Shanghai (Fluzoparib, Enzalutamide OR abiraterone acetate With

Active, not recruiting
  • Metastatic Castration Resistant Prostate Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Sep 23, 2022

Metastatic Castration-resistant Prostate Cancer Trial (Pembrolizumab, Enzalutamide)

Completed
  • Metastatic Castration-resistant Prostate Cancer
  • (no location specified)
Aug 16, 2022

Metastatic Castration-resistant Prostate Cancer Trial in San Francisco, Providence (Rucaparib, Copanlisib)

Active, not recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • San Francisco, California
  • +1 more
Nov 22, 2022

Metastatic Castration-resistant Prostate Cancer Trial in Mexico City (SV-102)

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • Mexico City, Mexico
    Hospital Diomed
Sep 14, 2022

Prostate Cancer Metastatic Trial (Pembrolizumab, Carboplatin, Cabazitaxel)

Not yet recruiting
  • Prostate Cancer Metastatic
  • (no location specified)
Sep 29, 2022

Prostatic Tumors, Metastatic Castration-Resistant Prostate Cancer Trial in Worldwide (Abiraterone Acetate, Prednisone,

Active, not recruiting
  • Prostatic Neoplasms
  • Metastatic Castration-Resistant Prostate Cancer
  • Abiraterone Acetate
  • +2 more
  • Los Angeles, California
  • +6 more
Jan 18, 2023

Metastatic Castration-resistant Prostate Cancer Trial in Beijing (1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01, 1.85 GBq (50 mCi) of

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • 1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01
  • +2 more
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Nov 6, 2022

Metastatic Castration-resistant Prostate Cancer Trial in Beijing (1.1 GBq (30 mCi) of 177Lu-P17-087, 1.1 GBq (30 mCi) of

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • 1.1 GBq (30 mCi) of 177Lu-P17-087
  • 1.1 GBq (30 mCi) of 177Lu-P17-088
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Oct 30, 2022

Metastatic Castration Resistant Prostate Cancer (mCRPC) Trial (Pidnarulex, Talazoparib)

Not yet recruiting
  • Metastatic Castration Resistant Prostate Cancer (mCRPC)
  • (no location specified)
Jun 15, 2022

Bone-Metastatic, Castration-Resistant Prostate Cancer Trial in United States (KX2-391)

Completed
  • Bone-Metastatic, Castration-Resistant Prostate Cancer
  • Chicago, Illinois
  • +4 more
Feb 1, 2023

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Trial in Bellinzona, London Borough of Sutton (Enzalutamide 40mg,

Recruiting
  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • Enzalutamide 40mg
  • +4 more
  • Bellinzona, Switzerland
  • +1 more
Nov 6, 2023

Metastatic Castration-resistant Prostate Cancer (mCRPC) Trial (225Ac-PSMA-R2, 68Ga-PSMA-R2)

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer (mCRPC)
  • (no location specified)
Aug 8, 2023

Castration-resistant Prostate Cancer Trial in Los Angeles (Apalutamide, Carotuximab)

Not yet recruiting
  • Castration-resistant Prostate Cancer
  • Los Angeles, California
    Cedars-Sinai Medical Center
Sep 6, 2022

Prostate Cancer Trial in Baltimore (DFMO, testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue)

Not yet recruiting
  • Prostate Cancer
  • Baltimore, Maryland
    Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Cen
Sep 22, 2023

Metastatic Castration-resistant Prostate Cancer Trial in Salt Lake City (Cabozantinib)

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • Salt Lake City, Utah
    Huntsman Cancer Institute at University of Utah
Nov 10, 2022

Prostate Cancer Metastatic Trial in New York, Knoxville (HB-302/HB-301 Alternating 2-Vector Therapy)

Recruiting
  • Prostate Cancer Metastatic
  • HB-302/HB-301 Alternating 2-Vector Therapy
  • New York, New York
  • +1 more
Feb 1, 2023